Last reviewed 2026-04-23 · How we verify

BMS-986259

Bristol-Myers Squibb · Phase 2 active Small molecule

At a glance

Generic name	BMS-986259
Sponsor	Bristol-Myers Squibb
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure (PHASE2)
A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function (PHASE1)
An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results